tbuckley/cabot-search huggingface dataset:
Abstract 3548: Selective targeting of pancreatic tumors lacking methylthioadenosine phosphorylase (MTAP)
Authors: Joseph R. Bertino, Kuo-Chi Lee, Nadine Johnson-Farley, Martin Lubin
Journal: Cancer Research (2011)

Abstract The pancreatic cancer cell line, Mia PACA, lacks MTAP, and as a result is unable to salvage adenine and methionine, products of methylthioadenosine (MTA) metabolism by MTAP, and is more sensitive to de novo purine synthesis inhibitors (thiopurines, methotrexate, azaserine and L-alanosine). In addition, MTAP deficiency creates a condition where normal, but not tumor tissues, can be protected from 5-fluorouracil (5-FU) toxicity by MTA. In normal tissue, MTA is converted to adenine, consuming 5-phosphoribose-1-pyrophosphate (PRPP) and competitively inhibiting phosphoribosylation of 5-FU (and subsequent cellular retention and inhibition of thymidylate synthase and incorporation into RNA). In MTAP deficient tumors, MTA can not generate adenine; the relative lack of adenine, and abundance of PRPP favors phosphoribosylation of 5-FU to nucleotides. The MTAP gene is linked to the tumor suppressor p16INK4 locus on chromosome 9p21. This locus is frequently deleted in human cancer. As a result, relative or complete MTAP deficiency is common in several human cancers, including pancreatic cancer (33%). We have transfected the Mia PACA cell line with MTAP cDNA and generated three sublines that express MTAP. The parenteral cell line lacking MTAP expression is more sensitive to 5-FU (4 h treatment), and toxicity is not ameliorated by pretreatment with MTA. In contrast, the three sublines expressing MTAP are a log less sensitive to 5FU, when pretreated with MTA. As pancreatic cancer is known to be somewhat responsive to treatment with 5-FU, but doses are limited by toxicity, the protection of the host from toxicity by MTA pretreatment may allow higher doses of 5-FU to be safely given and allow gemcitabine, another antimetabolite used to treat patients with pancreatic cancer, to be added in full doses. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3548. doi:10.1158/1538-7445.AM2011-3548
A piece of my mind. Watchers
Authors: S. Massad
Journal: JAMA (1995)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Authors: Luk H Vandenberghe, Lili Wang, Suryanarayan Somanathan, Yan Zhi, Joanita Figueredo, Roberto Calcedo, Julio Sanmiguel, Ravi A Desai, Christopher S Chen, Julie Johnston, Rebecca L Grant, Guangping Gao, James M Wilson
Journal: Nature Medicine (2006)
Modulation of vascular capacitance by angiotensin and nitroprusside: a mechanism of changes in pericardial pressure.
Authors: O A Smiseth, D E Manyari, J A Lima, N W Scott-Douglas, I Kingma, E R Smith, J V Tyberg
Journal: Circulation (1987)

The aim of the present study was to test the hypothesis that vasoactive drugs may modify left ventricular diastolic function by shifting blood between the systemic vascular bed and the heart, thereby changing pericardial and left ventricular pressure. The experiments were done in 10 open-chest, anesthetized, previously splenectomized dogs in which changes in pericardial surface pressure in response to intravenous sodium nitroprusside and angiotensin were related to changes in blood volume in the abdominal region. Blood volume was determined by blood pool scintigraphy (99mTc) and regions of interest were drawn in the liver and in the mesenteric area. Angiotensin was infused at rates that were adjusted to increase mean aortic pressure by 20 and 30 mm Hg, and nitroprusside was infused at rates to decrease mean aortic pressure by 30 and 50 mm Hg. Angiotensin increased pericardial pressure by 3 and 5 mm Hg at the respective doses and there were increments in left ventricular end-diastolic pressure (LVEDP) and left ventricular diameter (sonomicrometry). Angiotensin decreased blood volume in the mesenteric region by 14% and 17%, but did not significantly change blood volume in the liver region. Angiotensin increased portal venous pressure and decreased mesenteric blood volume, suggesting decreased mesenteric venous compliance. Nitroprusside had opposite effects: pericardial pressure was decreased by 5.5 and 6.5 mm Hg by the respective doses. The doses of nitroprusside increased blood volume in the mesenteric region by 14% and 20%, but did not significantly change blood volume in the liver region.(ABSTRACT TRUNCATED AT 250 WORDS)
THE BENEFICIAL EFFECT OF CHLOROMYCETIN IN BRUCELLOSIS 12
Authors: Theodore E. Woodward, Joseph E. Smadel, William A. Holbrook, William T. Raby
Journal: Journal of Clinical Investigation (1949)

Newer antibiotic agents have greatly extended the range of specific therapy in the group of infec- tious diseases with increasing rapidity.Much of this effort is directed against gram-negative bacilli in which group the Brucellae command a prominent position.Up to the present time the use of therapeutic agents in brucellosis has resulted in a certain measure of success, but with limitations, particularly from the point of view of failure to prevent recurrences.
Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Authors: Jeffrey L. Jackson
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Oral Pharmacotherapy for Male Sexual Dysfunction: A Guide to Clinical Management
Authors: William H. Salazar
Journal: Annals of Internal Medicine (2005)

Medical Writings: Book Notes2 August 2005Oral Pharmacotherapy for Male Sexual Dysfunction: A Guide to Clinical ManagementWilliam H. Salazar, MDWilliam H. Salazar, MDFrom Medical College of Georgia, Augusta, Georgia.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-143-3-200508020-00024 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Broderick GA, ed. 457 pages. Totowa, NJ: Humana Pr; 2005. ISBN 158829451X. Order phone 973-256-1699.Field of medicine: Internists, urologists, sex therapists, psychiatrists, cardiologists, endocrinologists, and gynecologists.Format: Hardcover book.Audience: Generalists who are on the front lines in diagnosing and treating erectile dysfunction, especially now that oral phosphodiesterase inhibitors are available, and urologists.Purpose: Written by eminent scholars and researchers in the field of male sexual dysfunction, this book presents a detailed review of the state-of-the-art treatment of the disorder. It will also help primary care physicians to select the best choice in diagnosis and treatment for male sexual ... Author, Article, and Disclosure InformationAffiliations: From Medical College of Georgia, Augusta, Georgia. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 2 August 2005Volume 143, Issue 3Page: 240KeywordsErectile dysfunctionInformation retrievalMedical conditionsPharmacologyPhosphodiesterasesProstatectomySexual dysfunctionSoftware toolsVeins ePublished: 2 August 2005 Issue Published: 2 August 2005 Copyright & PermissionsCopyright © 2005 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
A failure of mucocutaneous lymphangiogenesis may underlie the clinical features of lipoid proteinosis
Authors: T. Uchida, H. Hayashi, M. Inaoki, T. Miyamoto, W. Fujimoto
Journal: British Journal of Dermatology (2006)

Lipoid proteinosis (LiP) (OMIM 247100) is a rare autosomal recessive disease caused by loss of function mutations in the extracellular matrix protein 1 gene, ECM1, on chromosome 1q21. LiP is characterized clinically by hoarseness in early infancy, followed by waxy papules and plaques on the face and body along with pox-like and acneiform scars. We studied a 20-year-old Japanese woman with LiP. She was born of consanguineous parents. Biopsy specimens obtained from a nodule on the elbow were used for histopathology, immunohistology and electron microscopy. Exons 6 and 7 of ECM1 were amplified by polymerase chain reaction (PCR) from genomic DNA from the proband, her parents, her brother and an unrelated person. PCR products were sequenced to detect the mutation. Histopathological examination revealed an irregular mass of calcium beneath deposits of a hyaline material in the dermis. Immunofluorescence double staining showed that the CD31-positive microvascular density was increased but that staining for the lymphatic-specific hyaluronan receptor LYVE-1 was drastically diminished in lesional compared with nonlesional skin of the patient and with normal skin. Electron microscopy revealed marked concentric reduplication of basal laminae not only around blood vessels but also around solitary dermal cells positive for Weibel-Palade bodies scattered in the hyaline material. Sequencing of the PCR products revealed a homozygous frameshift mutation, 507delT, in exon 6. This led to a premature stop codon 23 bp downstream. The results of immunopathological and ultrastructural characterization suggest that a failure of mucocutaneous lymphangiogenesis may underlie the clinical features of LiP. Identification of mutation 507delT in a Japanese patient with LiP further supports the thesis that this mutation represents a recurrent mutation in ECM1 in patients with LiP. To our knowledge, this case represents the first report of calcinosis cutis occurring in LiP.
Regulation of Ca2+ signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin.
Authors: L R Jones, Y J Suzuki, W Wang, Y M Kobayashi, V Ramesh, C Franzini-Armstrong, L Cleemann, M Morad
Journal: Journal of Clinical Investigation (1998)

To probe the physiological role of calsequestrin in excitation-contraction coupling, transgenic mice overexpressing cardiac calsequestrin were developed. Transgenic mice exhibited 10-fold higher levels of calsequestrin in myocardium and survived into adulthood, but had severe cardiac hypertrophy, with a twofold increase in heart mass and cell size. In whole cell-clamped transgenic myocytes, Ca2+ channel- gated Ca2+ release from the sarcoplasmic reticulum was strongly suppressed, the frequency of occurrence of spontaneous or Ca2+ current-triggered "Ca2+ sparks" was reduced, and the spark perimeter was less defined. In sharp contrast, caffeine-induced Ca2+ transients and the resultant Na+-Ca2+ exchanger currents were increased 10-fold in transgenic myocytes, directly implicating calsequestrin as the source of the contractile-dependent pool of Ca2+. Interestingly, the proteins involved in the Ca2+-release cascade (ryanodine receptor, junctin, and triadin) were downregulated, whereas Ca2+-uptake proteins (Ca2+-ATPase and phospholamban) were unchanged or slightly increased. The parallel increase in the pool of releasable Ca2+ with overexpression of calsequestrin and subsequent impairment of physiological Ca2+ release mechanism show for the first time that calsequestrin is both a storage and a regulatory protein in the cardiac muscle Ca2+-signaling cascade. Cardiac hypertrophy in these mice may provide a novel model to investigate the molecular determinants of heart failure.
Associations between Early-life Infections, Antibiotic Use, and Asthma
Authors: A. Schroeder, L.M. Arguelles, R. Kumar, R. Gupta, D.M. Caruso, K.E. Meyer, B. Rowland, E. Frankis, J. Costello, J.A. Pongracic
Journal: Journal of Allergy and Clinical Immunology (2009)
Increased risk of arterial thromboembolic events after Staphylococcus aureus bacteremia: A matched cohort study
Authors: N. Mejer, N. Gotland, M.L. Uhre, H. Westh, H.C. Schønheyder, A. Petersen, A.G. Jensen, A.R. Larsen, R. Skov, T. Benfield
Journal: Journal of Infection (2015)
Hospitals need to change to ensure older people are treated with dignity, says commission
Authors: J. Wise
Journal: BMJ (2012)

An independent commission has called for fundamental changes so that hospitals and care homes ensure that all patients and residents are treated with dignity and respect. The commission, set up by the NHS Confederation, Age UK, and the Local Government Association, spent eight months reviewing and gathering evidence. Its draft report, Delivering Dignity , sets out 48 recommendations to stamp out undignified care. These include:
Treatment of Cardiogenic Shock by Emergency Aortic Balloon Valvuloplasty
Authors: MARK R. DESNOYERS
Journal: Annals of Internal Medicine (1988)

We used aortic balloon valvuloplasty to successfully treat two patients who had cardiogenic shock associated with calcific aortic stenosis. In both patients, the resulting reduction in mean aortic valve gradient and increase in calculated aortic valve area allowed prompt discontinuation of treatment with pressors and a return to near normal renal function. Both patients were discharged within 10 days after valvuloplasty and showed significant long-lasting clinical improvement. Aortic balloon valvuloplasty can reverse cardiogenic shock associated with calcific aortic stenosis.
Dendritic cell neoplasms: An overview
Authors: Sebastien Kairouz, Jana Hashash, Wadih Kabbara, Wassim Mchayleh, Imad A. Tabbara
Journal: American Journal of Hematology (2007)

Abstract Dendritic cell neoplasms are rare tumors that are being recognized with increasing frequency. They were previously classified as lymphomas, sarcomas, or histiocytic neoplasms. The World Health Organization (WHO) classifies dendritic cell neoplasms into five groups: Langerhans' cell histiocytosis, Langerhans' cell sarcoma, Interdigitating dendritic cell sarcoma/tumor, Follicular dendritic cell sarcoma/tumor, and Dendritic cell sarcoma, not specified otherwise (Jaffe, World Health Organization classification of tumors 2001; 273–289). Recently, Pileri et al. provided a comprehensive immunohistochemical classification of histiocytic and dendritic cell tumors (Pileri et al., Histopathology 2002;59:161–167). In this article, a concise overview regarding the pathological, clinical, and therapeutic aspects of follicular dendritic, interdigitating dendritic, and Langerhans' cell tumors is presented. Am. J. Hematol. 82:924–928, 2007. © 2007 Wiley‐Liss, Inc.
Cerebral Food Embolism Secondary to Esophageal-Cardiac Perforation
Authors: Hideo H. Itabashi
Journal: JAMA (1972)

A mentally retarded young man died with multiple miliary cerebral infarcts secondary to food embolization. His sudden and unexpected death resulted from an esophageal-cardiac perforation in the bed of a chronic esophageal ulcer into the left auricle. The infarcts were the likely result of unique embolization of food particles which gained entrance to the systemic circulation via the perforation. Food emboli were demonstrated in small arteries of virtually all organs examined.
From the Alcohol, Drug Abuse, and Mental Health Administration
Authors: Frederick K. Goodwin
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Patient's Story: Integrating the Patient- and Physician-centered Approaches to Interviewing
Authors: Robert C. Smith, Ruth B. Hoppe
Journal: Annals of Internal Medicine (1991)

▪Patients produce biopsychosocial stories that integrate material from the medical and personal aspects of their lives. Capturing the personal aspect of the story requires that a patient-centered approach to clinical interviewing complement the equally important physician-centered approach. Patient-centered interviewing actively involves the patient and ensures that his or her perceptions, needs, and concerns are articulated during the physician-patient interaction. In our article, we define patient-centered interviewing and provide a rationale for using it. We also describe how patient-centered interviewing is done, how it is integrated with the physician-centered approach, and how to understand the product of this complementary approach to clinical interviewing, the patient's biopsychosocial story.
NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome
Authors: N Villamor, L Conde, A Martínez-Trillos, M Cazorla, A Navarro, S Beà, C López, D Colomer, M Pinyol, M Aymerich, M Rozman, P Abrisqueta, T Baumann, J Delgado, E Giné, M González-Díaz, J M Hernández, E Colado, A R Payer, C Rayon, B Navarro, M José Terol, F Bosch, V Quesada, X S Puente, C López-Otín, P Jares, A Pereira, E Campo, A López-Guillermo
Journal: Leukemia (2012)
Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia-lymphoma with special emphasis on preconditioning regimen: a nationwide retrospective study
Authors: Takashi Ishida, Masakatsu Hishizawa, Koji Kato, Ryuji Tanosaki, Takahiro Fukuda, Shuichi Taniguchi, Tetsuya Eto, Yoshifusa Takatsuka, Yasushi Miyazaki, Yukiyoshi Moriuchi, Michihiro Hidaka, Koichi Akashi, Naokuni Uike, Hisashi Sakamaki, Yasuo Morishima, Koji Kato, Ritsuro Suzuki, Takeshi Nishiyama, Atae Utsunomiya
Journal: Blood (2012)
BMA meeting: NHS doctors must not be "muzzled," BMA chairman says
Authors: D. Cohen
Journal: BMJ (2009)

<h3>Introduction</h3> Pulmonary rehabilitation (PR) is a programme of individually prescribed physical exercise, education and self-management activities. PR is recommended in international guidelines for managing chronic obstructive pulmonary disease (COPD) and other chronic respiratory diseases. PR is still under-recognised in tuberculosis (TB) guidelines and PR is not available in many low and middle-income countries and for people with post-TB lung disease (PTBLD). The main aims of the study are to adapt and define a culturally appropriate PR programme in Kyrgyzstan for people living with PTBLD and to test, in a fully powered randomised controlled trial (RCT), the effectiveness of PR in improving exercise capacity for people living with PTBLD. <h3>Methods and analysis</h3> The study will be divided into three stages: <i>stage 1:</i> focus group discussions with patients living with PTBLD and interviews with PR referrers will be conducted to explore initial perceptions and inform the cultural adaptation, structure and content of PR. <i>Stage 2a:</i> a single-blind RCT evaluating the effectiveness of a culturally adapted 6-week PR programme on maximal exercise capacity, assessed by the incremental shuttle walking test, before and after PR. Participants will be additionally followed-up 12 weeks postbaseline. Additional outcomes will include health-related quality of life, respiratory symptoms, psychological well-being and physical function. <i>Stage 2b:</i> participants’ experience of PR will be collected through interviews and using a log book and a patient evaluation form. Staff delivering PR will be interviewed to explore their experience of delivering the intervention and refining the delivery for future implementation. <h3>Ethics and dissemination</h3> The study was approved 22/07/2019 by Ethics Committee National Center for Cardiology and Internal Medicine (reference number 17) and by University of Leicester ethics committee (reference number 22293). Study results will be disseminated through appropriate peer-reviewed journals, national and international respiratory/physiotherapy conferences, social media, and through patient and public involvement events in Kyrgyzstan and in the UK. <h3>Trial registration number</h3> ISRCTN11122503.